Journal article
Cardiovasc Res
27/07/2021
117
e110 - e113
Antithrombotic, Antiviral, COVID-19, Immunomodulation, Randomized trial, Aged, Anti-Inflammatory Agents, Antiviral Agents, COVID-19, Cardiovascular Diseases, Cause of Death, Female, Fibrinolytic Agents, Heart Disease Risk Factors, Humans, Male, Middle Aged, Research Design, Risk Assessment, Time Factors, Treatment Outcome